MetaCap

Annovis Bio (ANVS) vs Quantum Cyber N.V. (QUCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quantum Cyber N.V. (QUCY) has outperformed Annovis Bio (ANVS) over the past year, losing 48.7% versus a loss of 81.2%. Over five years, QUCY leads with a -94.8% price change compared with -97.2% for ANVS. Quantum Cyber N.V. is the larger company by market cap ($44.7 million vs $44.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANVS-81.23%QUCY-48.75%
+273%+87%-99%
Nov 21, 20251 yearNov 20, 2026
ANVS-97.38%QUCY-94.78%
+197%+43%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANVS versus QUCY key metrics
MetricANVSQUCY
Share price$0.7113$0.512
Market cap$44.12M$44.67M
1-day change-4.96%-7.25%
YTD return-79.44%-54.29%
1-year return-81.23%-48.75%
5-year return-97.24%-94.80%
EPS (TTM)$-1.55$-2.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$537.08K
Revenue growth (YoY)—-39.92%
Net income (latest FY)$-28.85M$-16.21M
Gross margin—72.58%
Operating margin—-3004.97%
Net margin—-3018.31%
52-week high$5.50$4.93
52-week low$0.62$0.30
Distance from 52-week high-87.07%-89.61%
Analyst consensusnonenone
Avg. price target upside+1376.17%+1657.81%
Average volume1.82M528.02K
Shares outstanding62.02M87.24M
Employees710
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QUCY has outperformed ANVS by 32.5 percentage points over the past year.

About Annovis Bio

ANVS stock →

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Quantum Cyber N.V.

QUCY stock →

Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ANVS vs QUCY FAQ

Which is bigger, Annovis Bio or Quantum Cyber N.V.?

Quantum Cyber N.V. (QUCY) is larger, with a market capitalization of $44.67M compared with $44.12M for Annovis Bio (ANVS).

Which stock has performed better over the past year, ANVS or QUCY?

QUCY returned -48.75% over the past 12 months, compared with -81.23% for ANVS (price return, excluding dividends). Past performance does not predict future results.

Are Annovis Bio and Quantum Cyber N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons